Rytary Alternatives Compared
| Rytary (carbidopa / levodopa) | Carbidopa / levodopa | Sinemet (carbidopa / levodopa) |
|
|---|
| Rytary (carbidopa / levodopa) | Carbidopa / levodopa | Sinemet (carbidopa / levodopa) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Rytary is an extended-release (long-lasting) medication that may be used for the treatment of Parkinson's disease that is available in four different strengths: Rytary 23.75/95, Rytary 36.25/145... View more |
Prescription only
Carbidopa/levodopa is a medication that may be used for the treatment of Parkinson's disease. Available as immediate-release tablets, extended-release tablets, and extended-release capsules... View more |
Prescription only
Sinemet is a medication that may be used for the treatment of Parkinson's disease that is available in three different strengths: Sinemet 25/100, Sinemet 25/250, and Sinemet 10/100. Dyskinesias... View more |
Related suggestions Parkinson's Disease
Popular comparisons
|
|||||||||||||||||||||||
| More about Rytary (carbidopa / levodopa) | More about Carbidopa / levodopa | More about Sinemet (carbidopa / levodopa) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Rytary has an average rating of 6.2 out of 10 from a total of 30 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 33% reported a negative effect. |
Carbidopa / levodopa has an average rating of 7.3 out of 10 from a total of 94 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 20% reported a negative effect. |
Sinemet has an average rating of 7.8 out of 10 from a total of 30 ratings on Drugs.com. 68% of reviewers reported a positive effect, while 11% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Rytary prices |
View all Carbidopa / levodopa prices |
View all Sinemet prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other carbidopa / levodopa brands include: Atamet, Crexont, Dhivy, Duopa, Parcopa, Sinemet | Atamet, Crexont, Dhivy, Duopa, Parcopa, Rytary, Sinemet | Other carbidopa / levodopa brands include: Atamet, Crexont, Dhivy, Duopa, Parcopa, Rytary | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
2.3 hours |
2.3 hours |
2.3 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 490 drugs are known to interact with Rytary:
|
A total of 490 drugs are known to interact with Carbidopa / levodopa:
|
A total of 490 drugs are known to interact with Sinemet:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
January 07, 2015 |
May 02, 1975 |
May 02, 1975 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.